{"schema_version":"alpha-company-profile-public-v2","slug":"atara-biotherapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc","published_on":"2026-09-18T04:46:42.397789+00:00","last_reviewed_on":"2026-09-18T04:46:42.397789+00:00","identity":{"legal_name":"Atara Biotherapeutics, Inc.","display_name":"Atara Biotherapeutics, Inc.","headline":"Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies.","description":"Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as we","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001604464","logo":"https://cdn.brandfetch.io/ticker/atra/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/atra/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Atara Biotherapeutics, Inc. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-09-18T04:46:42.397789+00:00"},"security_listings":[{"ticker":"ATRA","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Atara Biotherapeutics, Inc.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/atara-biotherapeutics-inc","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-09-18T04:46:42.397789+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":11,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":11,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":2,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":11,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":11,"corroborated_claims":0,"sources":2,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-09-18T04:46:42.397789+00:00","observed_at":"2026-09-18T04:46:42.397789+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"atara-biotherapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc"},"publication":{"published_at":"2026-09-18T04:46:42.397789+00:00","last_reviewed_at":"2026-09-18T04:46:42.397789+00:00","as_of":"2026-09-18T04:46:42.397789+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/atara-biotherapeutics-inc","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"atara-biotherapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc","as_of":"2026-09-18T04:46:42.397789+00:00","last_reviewed_at":"2026-09-18T04:46:42.397789+00:00","identity":{"legal_name":"Atara Biotherapeutics, Inc.","display_name":"Atara Biotherapeutics, Inc.","description":"Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as we","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001604464","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNAS","ticker":"ATRA","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"8d5d73ec-0142-4f22-868d-1f3494ba4adc","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-09-18","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":false,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"anhco-nguyen-ph-d","display_name":"AnhCo Nguyen, Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null},{"person_slug":"gregory-a-ciongoli","display_name":"Gregory A. Ciongoli","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null},{"person_slug":"james-huang","display_name":"James Huang","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null},{"person_slug":"matthew-k-fust","display_name":"Matthew K. Fust","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2014-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null},{"person_slug":"nachi-subramanian","display_name":"Nachi Subramanian","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null},{"person_slug":"william-k-heiden","display_name":"William K. Heiden","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2015-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"Atara Biotherapeutics, Inc. DEF 14A 2026-04-24","source_url":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526177285/atra-20260424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-24","last_checked_at":"2026-04-24T23:13:00.521+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc#profile","url":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc","dateModified":"2026-09-18T04:46:42.397789+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc#organization","legalName":"Atara Biotherapeutics, Inc.","name":"Atara Biotherapeutics, Inc.","description":"Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as we","url":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"AnhCo Nguyen, Ph.D.","url":"https://registry.alpha.ac/people/anhco-nguyen-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Gregory A. Ciongoli","url":"https://registry.alpha.ac/people/gregory-a-ciongoli"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2025-01-01","member":{"@type":"Person","name":"James Huang","url":"https://registry.alpha.ac/people/james-huang"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2014-01-01","member":{"@type":"Person","name":"Matthew K. Fust","url":"https://registry.alpha.ac/people/matthew-k-fust"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2025-01-01","member":{"@type":"Person","name":"Nachi Subramanian","url":"https://registry.alpha.ac/people/nachi-subramanian"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2015-01-01","member":{"@type":"Person","name":"William K. Heiden","url":"https://registry.alpha.ac/people/william-k-heiden"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/atara-biotherapeutics-inc"},"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"}},"canonical_source":"aegis_canonical"}